---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-004268"
form_type: "8-K"
ticker: "ACTU"
cik: "0001652935"
company_name: "ACTUATE THERAPEUTICS, INC."
filed_at: "2026-05-22T20:43:53+00:00"
generated_at: "2026-05-22T20:51:58.251881+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Actuate Therapeutics holds 2026 Annual Meeting; elects Fletcher and Keyes as directors, ratifies Crowe LLP as auditor

## Summary
- Elected Aaron G.L. Fletcher, Ph.D. and Jason Keyes as Class II directors for three-year terms through 2029.
- Fletcher received 14,877,247 for, 1,883,025 withheld; Keyes received 16,727,875 for, 32,397 withheld.
- Ratified Crowe LLP as independent auditor for FY 2026 with 18,571,817 for, 50,023 against, 9,741 abstain.
- Broker non-votes: 1,871,309 on director elections; none on auditor ratification.

## SEC filing metadata
- accession: 0001683168-26-004268
- form_type: 8-K
- ticker: ACTU
- cik: 0001652935
- company_name: ACTUATE THERAPEUTICS, INC.
- filed_at: 2026-05-22T20:43:53+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652935/000168316826004268/0001683168-26-004268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652935/000168316826004268/actuate_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-004268
- JSON: https://secwatch.observer/filing/0001683168-26-004268.json
- Plain text: https://secwatch.observer/filing/0001683168-26-004268.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.